Intervention

Bemcentinib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4
Recruiting0
Common conditions12
Lead sponsors shown1
Advertisement

Clinical trials

4 shown
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneNCT05469178 · 2023-03-03
TERMINATED
A Study to Investigate 14C-bemcentinib in Healthy Male SubjectsNCT06469138 · 2022-08-02
COMPLETED
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)NCT03184571 · 2017-10-02
COMPLETED
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerNCT02424617 · 2015-04-19
COMPLETED

Trial status mix

COMPLETED3
TERMINATED1

Phase mix

PHASE13
PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.